2021/04/12
On March 11th, the National Medical Products Administration (NMPA) issued the “Notice Recognizing Excellent Units in the National Adverse Drug Reactions Monitoring and Evaluation 2020”. In this notice, Beijing Beilu Pharmaceutical Co., Ltd. was awarded the “National Outstanding Unit for the Adverse Drug Reaction Monitoring and Evaluation”.
Here, we would like to express our gratitude and congratulations to all staff of the Pharmacovigilance Department! Wish them could make persistent efforts in the future work and achieve greater results!